Pichamol Jirapinyo1, Diogo T H de Moura2, William Y Dong3, Galileu Farias4, Christopher C Thompson1. 1. Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts, USA. 2. Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts, USA; Gastroenterology Department, Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil. 3. Stony Brook University, Stony Brook, New York, USA. 4. Gastroenterology Department, Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
Abstract
BACKGROUND AND AIMS: Argon plasma coagulation (APC) of gastrojejunal anastomosis (GJA) is effective in treating weight regain after Roux-en-Y gastric bypass (RYGB). This study aims to compare the efficacy of different APC settings for treating weight regain. METHODS: This was a single-center retrospective study of patients who had undergone RYGB and then underwent APC from 2014 to 2018 for weight regain. Patients receiving only low-dose APC (45-55 W) or high-dose APC (70-80 W) were compared. The primary outcome was the difference in percentage total weight loss (% TWL) between the groups at 6 and 12 months after the last treatment. Secondary outcomes were technical success, adverse events (AEs), and predictors of weight loss at 12 months. RESULTS: Two hundred seventeen patients met the inclusion criteria and underwent 411 APC sessions. Of these, 116 (53.5%) patients underwent 267 low-dose APC sessions (2.4 ± 1.5 sessions/patient) and 101 (46.5%) patients underwent 144 high-dose APC sessions (1.4 ± 0.7 sessions/patient). Follow-up rates were 82.9% and 75.3% at 6 and 12 months. At 6 months, the low- and high-dose groups experienced 7.3% ± 6.6% and 8.1% ± 7.4% TWL, respectively (P = .41). At 12 months, the low- and high-dose groups experienced 5.1% ± 8.5% and 9.7% ± 10.0% TWL, respectively (P = .008). Technical success was 100%. The overall AE rate was 8.0%; the most common AE was GJA stenosis (4.6%). The GJA stenosis rate was similar for the low- and high-dose groups (3.0% vs 7.6%, P = .06). High-dose APC remained a significant predictor of greater weight loss at 1 year after controlling for confounders. CONCLUSION: APC is effective at treating weight regain after RYGB, and higher-watt APC was associated with greater weight loss.
BACKGROUND AND AIMS: Argon plasma coagulation (APC) of gastrojejunal anastomosis (GJA) is effective in treating weight regain after Roux-en-Y gastric bypass (RYGB). This study aims to compare the efficacy of different APC settings for treating weight regain. METHODS: This was a single-center retrospective study of patients who had undergone RYGB and then underwent APC from 2014 to 2018 for weight regain. Patients receiving only low-dose APC (45-55 W) or high-dose APC (70-80 W) were compared. The primary outcome was the difference in percentage total weight loss (% TWL) between the groups at 6 and 12 months after the last treatment. Secondary outcomes were technical success, adverse events (AEs), and predictors of weight loss at 12 months. RESULTS: Two hundred seventeen patients met the inclusion criteria and underwent 411 APC sessions. Of these, 116 (53.5%) patients underwent 267 low-dose APC sessions (2.4 ± 1.5 sessions/patient) and 101 (46.5%) patients underwent 144 high-dose APC sessions (1.4 ± 0.7 sessions/patient). Follow-up rates were 82.9% and 75.3% at 6 and 12 months. At 6 months, the low- and high-dose groups experienced 7.3% ± 6.6% and 8.1% ± 7.4% TWL, respectively (P = .41). At 12 months, the low- and high-dose groups experienced 5.1% ± 8.5% and 9.7% ± 10.0% TWL, respectively (P = .008). Technical success was 100%. The overall AE rate was 8.0%; the most common AE was GJA stenosis (4.6%). The GJA stenosis rate was similar for the low- and high-dose groups (3.0% vs 7.6%, P = .06). High-dose APC remained a significant predictor of greater weight loss at 1 year after controlling for confounders. CONCLUSION: APC is effective at treating weight regain after RYGB, and higher-watt APC was associated with greater weight loss.
Authors: Rena C Moon; Andre F Teixeira; Manoel Galvao Neto; Natan Zundel; Bruno Queiroz Sander; Flavio Mitidieri Ramos; Felipe Matz; Giorgio A Baretta; Luiz Gustavo de Quadros; Eduardo Grecco; Thiago Souza; Sergio A Barrichello; Admar Concon Filho; Eduardo Nobuyuki Usuy; Artagnan Menezes Barbosa de Amorim; Muhammad A Jawad Journal: Obes Surg Date: 2018-09 Impact factor: 4.129
Authors: Christopher J Goulet; James A Disario; Lyska Emerson; Kristen Hilden; Richard Holubkov; John C Fang Journal: Gastrointest Endosc Date: 2007-03 Impact factor: 9.427
Authors: Giorgio A P Baretta; Helga C A W Alhinho; Jorge Eduardo F Matias; João Batista Marchesini; João Henrique F de Lima; Celso Empinotti; Josemberg M Campos Journal: Obes Surg Date: 2015-01 Impact factor: 4.129
Authors: Lars Sjöström; Kristina Narbro; C David Sjöström; Kristjan Karason; Bo Larsson; Hans Wedel; Ted Lystig; Marianne Sullivan; Claude Bouchard; Björn Carlsson; Calle Bengtsson; Sven Dahlgren; Anders Gummesson; Peter Jacobson; Jan Karlsson; Anna-Karin Lindroos; Hans Lönroth; Ingmar Näslund; Torsten Olbers; Kaj Stenlöf; Jarl Torgerson; Göran Agren; Lena M S Carlsson Journal: N Engl J Med Date: 2007-08-23 Impact factor: 91.245
Authors: Maria Paula Carlin Cambi; Giorgio Alfredo Pedroso Baretta; Daniéla De Oliveira Magro; Cesar Luiz Boguszewski; Igor Braga Ribeiro; Pichamol Jirapinyo; Diogo Turiani Hourneaux de Moura Journal: Obes Surg Date: 2021-01-03 Impact factor: 4.129
Authors: Manoel Galvao Neto; Vitor Ottoboni Brunaldi; Eduardo Grecco; Lyz Bezerra Silva; Luiz Gustavo de Quadros; Thiago Ferreira de Souza; André Teixeira; Helmut Wagner Poti de Morais; João Henrique Felicio de Lima; Admar Concon Filho; Artagnan Amorim; Marcelo Falcão de Santana; Newton Teixeira; João Caetano Marchesini Journal: Obes Surg Date: 2021-11-22 Impact factor: 4.129
Authors: Donna Maria Abboud; Rebecca Yao; Babusai Rapaka; Rabih Ghazi; Omar M Ghanem; Barham K Abu Dayyeh Journal: Front Endocrinol (Lausanne) Date: 2022-07-14 Impact factor: 6.055